X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Nanjing King-friend Biochemical Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2023
Details:
Plerixafor Injection is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lead Product(s): Plerixafor
Therapeutic Area: Oncology Product Name: Plerixafor-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Under the agreement, Meitheal gains exclusive rights to commercialize XTMAB-16, a monoclonal antibody which aims to treat people with sarcoidosis, in North America and Xentria remains responsible for clinical development and retains the marketing rights in all other countries.
Lead Product(s): XTMAB-16
Therapeutic Area: Immunology Product Name: XTMAB-16
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Xentria
Deal Size: $680.0 million Upfront Cash: $45.0 million
Deal Type: Licensing Agreement June 27, 2023
Details:
Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Premier
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Lead Product(s): Enoxaparin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
